Veracyte (VCYT) Competitors $26.34 -1.17 (-4.25%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$26.46 +0.12 (+0.46%) As of 07/7/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VCYT vs. ADPT, BEAM, GH, TWST, TXG, OPCH, RDNT, BTSG, SHC, and SGRYShould you be buying Veracyte stock or one of its competitors? The main competitors of Veracyte include Adaptive Biotechnologies (ADPT), Beam Therapeutics (BEAM), Guardant Health (GH), Twist Bioscience (TWST), 10x Genomics (TXG), Option Care Health (OPCH), RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), and Surgery Partners (SGRY). These companies are all part of the "medical" sector. Veracyte vs. Its Competitors Adaptive Biotechnologies Beam Therapeutics Guardant Health Twist Bioscience 10x Genomics Option Care Health RadNet BrightSpring Health Services Sotera Health Surgery Partners Adaptive Biotechnologies (NASDAQ:ADPT) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership. Is ADPT or VCYT more profitable? Veracyte has a net margin of 7.13% compared to Adaptive Biotechnologies' net margin of -74.84%. Veracyte's return on equity of 6.14% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Adaptive Biotechnologies-74.84% -62.79% -24.55% Veracyte 7.13%6.14%5.60% Which has higher valuation & earnings, ADPT or VCYT? Veracyte has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptive Biotechnologies$178.96M9.97-$159.49M-$0.96-12.23Veracyte$445.76M4.63$24.14M$0.4164.24 Does the media prefer ADPT or VCYT? In the previous week, Adaptive Biotechnologies had 4 more articles in the media than Veracyte. MarketBeat recorded 7 mentions for Adaptive Biotechnologies and 3 mentions for Veracyte. Veracyte's average media sentiment score of 1.24 beat Adaptive Biotechnologies' score of 0.50 indicating that Veracyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Veracyte 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, ADPT or VCYT? Adaptive Biotechnologies has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Do analysts prefer ADPT or VCYT? Adaptive Biotechnologies presently has a consensus price target of $10.57, indicating a potential downside of 9.95%. Veracyte has a consensus price target of $40.90, indicating a potential upside of 55.28%. Given Veracyte's higher probable upside, analysts plainly believe Veracyte is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Veracyte 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 Do institutionals and insiders have more ownership in ADPT or VCYT? 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 6.4% of Adaptive Biotechnologies shares are owned by insiders. Comparatively, 1.4% of Veracyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryVeracyte beats Adaptive Biotechnologies on 11 of the 16 factors compared between the two stocks. Get Veracyte News Delivered to You Automatically Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCYT vs. The Competition Export to ExcelMetricVeracyteMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.15B$6.86B$5.52B$9.02BDividend YieldN/A1.21%5.24%4.08%P/E Ratio64.2525.5527.1920.04Price / Sales4.63111.05413.81108.84Price / Cash26.5321.4826.2128.59Price / Book1.744.727.925.55Net Income$24.14M$173.18M$3.17B$248.49M7 Day Performance-3.59%0.34%1.78%4.87%1 Month Performance-4.08%-2.74%1.26%6.63%1 Year Performance21.38%25.56%33.30%20.38% Veracyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCYTVeracyte3.7485 of 5 stars$26.34-4.3%$40.90+55.3%+22.3%$2.15B$445.76M64.25790Positive NewsADPTAdaptive Biotechnologies3.4104 of 5 stars$11.65-1.2%$10.57-9.3%+231.6%$1.77B$189.53M-12.14790BEAMBeam Therapeutics2.4532 of 5 stars$17.01+1.3%$48.75+186.6%-16.9%$1.71B$63.52M-3.69510GHGuardant Health3.7976 of 5 stars$52.04+2.3%$53.76+3.3%+72.3%$6.45B$739.02M-15.352,021TWSTTwist Bioscience4.5244 of 5 stars$36.79+2.4%$50.40+37.0%-26.6%$2.20B$312.97M-11.32990News CoveragePositive NewsTXG10x Genomics4.9104 of 5 stars$11.58-1.3%$14.96+29.2%-36.3%$1.43B$610.78M-8.911,240Positive NewsOPCHOption Care Health4.3381 of 5 stars$32.48+0.7%$35.50+9.3%+15.6%$5.32B$5.00B26.198,088Positive NewsRDNTRadNet4.1997 of 5 stars$56.91-0.4%$69.60+22.3%-7.3%$4.27B$1.83B-132.3511,021Positive NewsBTSGBrightSpring Health Services1.4019 of 5 stars$23.59+0.2%$24.90+5.6%+97.5%$4.15B$11.27B84.2535,000Analyst UpgradeSHCSotera Health2.9866 of 5 stars$11.12-1.8%$16.00+43.9%-3.0%$3.16B$1.10B139.023,000SGRYSurgery Partners2.5437 of 5 stars$22.23+1.3%$33.56+50.9%-5.9%$2.85B$3.17B-14.5315,000 Related Companies and Tools Related Companies Adaptive Biotechnologies Competitors Beam Therapeutics Competitors Guardant Health Competitors Twist Bioscience Competitors 10x Genomics Competitors Option Care Health Competitors RadNet Competitors BrightSpring Health Services Competitors Sotera Health Competitors Surgery Partners Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VCYT) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veracyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
